Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SinoBiomed Wins Approval Of Recombinant Growth Factor

publication date: Apr 13, 2007
Distribution To Begin In Second Half Of 2007 -- SinoBiomed (SOBM.OB) announced that its subsidiary Shanghai Wanxing received approval in China for its lyophilized recombinant human acidic fibroblast growth factor for external use (rhaFGF). The drug is indicated for ulceration, including deep burns and chronic ulcers caused by wounds, diabetes, vascular diseases and bed sores. Before distributing the drug, Shanghai Wanxing must also win GMP Certification. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here